Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand

BACKGROUND: Targeted treatment with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) is superior to systemic chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR gene mutations. Detection of EGFR mutations is a challenge in many patients due to the lack of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Aye, Phyu Sin, Tin Tin, Sandar, McKeage, Mark James, Khwaounjoo, Prashannata, Cavadino, Alana, Elwood, J. Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362551/
https://www.ncbi.nlm.nih.gov/pubmed/32664868
http://dx.doi.org/10.1186/s12885-020-07162-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362551/
https://www.ncbi.nlm.nih.gov/pubmed/32664868
http://dx.doi.org/10.1186/s12885-020-07162-z

Ejemplares similares